Emergent BioSolutions (NYSE:EBS) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a research note released on Monday.

A number of other equities analysts also recently weighed in on the company. Benchmark boosted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Stock Up 2.1 %

Shares of NYSE EBS opened at $9.70 on Monday. The stock has a market cap of $525.28 million, a P/E ratio of -2.36 and a beta of 1.62. The firm has a 50 day moving average price of $9.71 and a 200 day moving average price of $9.12. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 52-week low of $1.48 and a 52-week high of $15.10.

Institutional Investors Weigh In On Emergent BioSolutions

Several large investors have recently modified their holdings of the stock. American Century Companies Inc. boosted its holdings in Emergent BioSolutions by 23.4% in the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock valued at $20,437,000 after purchasing an additional 404,667 shares during the period. State Street Corp increased its position in shares of Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares during the period. Invesco Ltd. increased its position in shares of Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock valued at $14,722,000 after buying an additional 638,995 shares during the period. Millennium Management LLC boosted its stake in Emergent BioSolutions by 83.0% during the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after acquiring an additional 671,947 shares in the last quarter. Finally, Oak Hill Advisors LP bought a new stake in Emergent BioSolutions during the third quarter worth about $9,296,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.